MAFG-AS1/MAFG positive feedback loop contributes to cisplatin resistance in bladder urothelial carcinoma through antagonistic ferroptosis
Liang Xiang,Qinghai Zeng,Jianye Liu,Mengqing Xiao,Dong He,Qun Zhang,Dan Xie,Minhua Deng,Yuxing Zhu,Yan Liu,Hao Bo,Xiaoming Liu,Ming Zhou,Wei Xiong,Yanhong Zhou,Jianda Zhou,Xiaohui Li,Ke Cao
DOI: https://doi.org/10.1016/j.scib.2021.01.027
IF: 18.9
2021-09-01
Science Bulletin
Abstract:<p>Though promoting ferroptosis can reduce cisplatin resistance in tumor cells, ferroptosis and cisplatin resistance in bladder urothelial carcinoma (BUC) following long non-coding RNAs (lncRNAs) is largely unknown. Here, we found the highly expressed lncRNA MAFG-AS1 in BUC, and its inhibition increased the sensitivity of BUC cells to cisplatin by promoting ferroptosis. Mechanically, binding to iron chaperone PCBP2 facilitated the recruitments of MAFG-AS1 to deubiquitinase UCHL5, thus stabilizing PCBP2 protein itself. Then PCBP2 was confirmed to interact with ferroportin 1 (FPN1), an iron export protein, leading to inhibition of ferroptosis. Moreover, the expression of MAFG-AS1 was regulated by the transcriptional factor MAFG. Interestingly, MAFG-AS1 stimulated MAFG transcription by recruiting acetylase EP300 to promote the H3K27ac at genomic locus of MAFG, forming a MAFG-AS1/MAFG positive feedback loop. In patient samples, higher expression of MAFG-AS1 and MAFG in BUC tissues was significantly correlated with T status and N status, such that MAFG-AS1, MAFG, and the combination of the two were independent prognostic indicators and chemotherapy sensitivity predictive biomarkers for BUC patients. These findings suggest that inhibition of MAFG-AS1 and MAFG can increase the sensitivity of BUC cells to cisplatin through promoting ferroptosis, indicating the novel chemotherapy sensitivity biomarkers and therapeutic target for BUC.</p>
multidisciplinary sciences